anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Fibrosis is a hallmark of chronic disease. Although fibroblasts are involved, it is unclear to what extent endothelial cells also might contribute. We detected increased expression of the transcription factor Sox9 in endothelial cells in several different mouse fibrosis models. These models included systolic heart failure induced by pressure overload, diastolic heart failure induced by high-fat diet and nitric oxide synthase inhibition, pulmonary fibrosis induced by bleomycin treatment, and liver fibrosis due to a choline-deficient diet. We also observed up-regulation of endothelial SOX9 in cardiac tissue from patients with heart failure. To test whether SOX9 induction was sufficient to cause disease, we generated mice with endothelial cell-specific overexpression of Sox9, which promoted fibrosis in multiple organs and resulted in signs of heart failure. Endothelial Sox9 deletion prevented fibrosis and organ dysfunction in the two mouse models of heart failure as well as in the lung and liver fibrosis mouse models. Bulk and single-cell RNA sequencing of mouse endothelial cells across multiple vascular beds revealed that SOX9 induced extracellular matrix, growth factor, and inflammatory gene expression, leading to matrix deposition by endothelial cells. Moreover, mouse endothelial cells activated neighboring fibroblasts that then migrated and deposited matrix in response to SOX9, a process partly mediated by the secreted growth factor CCN2, a direct SOX9 target; endothelial cell-specific Sox9 deletion reversed these changes. These findings suggest a role for endothelial SOX9 as a fibrosis-promoting factor in different mouse organs during disease and imply that endothelial cells are an important regulator of fibrosis.
The proposed study will involve the development and pilot testing of an interactive computerized tailored intervention program for HIV/STI prevention among at-risk heterosexually active African-American STI clinic patients, aged 18-29. The Attitude-Social-Influence Efficacy (ASE) model will serve as a conceptual foundation for the intervention and tailored feedback, which will assess and give feedback to participants separately for main/steady and other/casual partners. Individual modules will be developed for key theoretical concepts and subsequently tied together into an integrated system. The tailored feedback will additionally be enhanced by crafting intervention messages to be high in message sensation value and by developing interactive intervention activities for skill-building, which will be guided by both Social Cognitive Theory and skills training principles. The computerized intervention will be developed and guided using data collected from the target audience to ensure an empirically-based approach to tailoring. The intervention will also be developed with input from the target audience in order to maximize the appropriateness and persuasiveness of the feedback and the program, including interactive components. The final year of the project will entail a pilot test of the intervention in order to gather preliminary data on the acceptability and efficacy of such an intervention for increasing safer sexual behaviors among at-risk heterosexually active African-Americans.

The specific aims of the study are: 1) to develop tailored feedback on HIV/STI prevention based on the ASE model, including condom attitudes, social influences, self-efficacy including communication / negotiation skills, partner and behavioral risk, correct condom use, and condom stages of change; 2) to enhance the delivery of the tailored messages using sensation-seeking targeting (SENTAR) and skill-building using interactive activities guided by Social Cognitive Theory (SCT) and skills training principles; 3) to tie the individual theoretical modules together and develop a computerized intervention program for HIV/STI prevention, which provides tailored risk reduction messages to participants based upon an assessment of participant characteristics; 4) to develop empirically sound cutpoints, specific to the target audience, to guide the message tailoring; and 5) in a wait-list control group design, to pilot test the intervention for acceptability and efficacy in increasing condom use with main and casual partners among at-risk heterosexually active African-Americans, relative to a "usual care" comparison condition.
1450442 Plant extracts E M COBB 22 Oct 1974 [22 Oct 1973 19 June 1974] 49089/73 and 27204/74 Addition to 1335181 Heading A5B Anti-tumour compounds designated Kardollin A, B, C, D, E., E 11 , F and G and characterised by their infra-red spectra and chromatographic and other properties, are obtained by extracting plant material of species of plants belonging to the Compositae family, Tribe Cynareae, Subtribe Centaureineae with organic solvents, evaporating the solvent from the extracts at reduced pressure and separating the compounds by chromatography. The compounds are belived to be of the type of sesquiterpene lactone alkaloids. The solvent used for the extraction is preferably ethanol, chloroform, methanol, petrol ether or a mixture thereof. The chromatographic separation may be effected on a column of neutral silica-using a benzene/acetone or chloroform/methanol solvent system for development and elution. The examples relate to the extraction of plant material of Carduus benedictus and Carduus marianus. The claims also relate to particular chloroform, methanol and petrol ether extracts obtained by specified methods. Pharmaceutical and veterinary compositions having antitumour activity comprise one of the above Kardollins or extracts together with pharmaceutically suitable carrier. The compositions may be administered orally, topically or parenterally.
INTRODUCTION: Chimeric antigen receptor (CAR) T-cells have revolutionized cancer treatment, showing significant success, including treatment of pediatric B-cell acute lymphoblastic leukemia (B-ALL). Despite their efficacy, cytokine release syndrome (CRS) emerges as a common early adverse effect that can be life threatening in severe cases, resulting from the immune system's targeted activation against tumors.
AREAS COVERED: This review concentrates on CRS in children and young adults undergoing CAR T-cell therapy for B-ALL. It explores CRS pathophysiology, clinical presentation, and incidence, emphasizing the importance of a consensus definition and grading to homogenize the treatment according to the severity of symptoms. We will discuss the standard of care treatment of CRS but also novel approaches. We will highlight the importance of managing CRS without compromising the efficacy of immune cell activation against tumors.
EXPERT OPINION: As CAR T-cell therapy in pediatric B-ALL become increasingly available and used, optimal management of CRS becomes increasingly important. Early recognition and timely management has improved. Further information will aid us to identify optimal timing of tocilizumab and corticosteroids. Continued bench research coupled with clinical studies and biomarker discovery will allow for valuable insights into CRS pathophysiology and patient and/or cell-targeted treatments.
PURPOSE: To obtain a gelatinous dentifrice containing a peroxide and a viscosity stabilization system. CONSTITUTION: This composition for oral cavity in a form of a transparent gelatinous dentifrice comprises hydrogen peroxide and a polyoxyethylene- polyoxypropylene copolymer. The gel comprises >30% and <50% of glycerol so that it is stabilized so as to prevent loss in viscosity at a low temperature. The weight ratio of the glycerol and the copolymer has to be 1:0.7 to 1:0.4. The stability of hydrogen peroxide is advantageous when the composition has pH<3. Phosphoric acid is convenient as an acidifying agent.
This invention describes the development of targeted small molecule inhibitors of the inv(16) fusion, the causative agent in ~12% of acute myeloid leukemia (AML). The inv(16) fusion results in expression of the CBFβ-SMMHC fusion protein in the blood cells of afflicted patients. The present invention provides compounds which inhibit the function of both CBFβ and the CBFβ-SMMHC fusion. These compounds block the growth of an inv(16) leukemia cell line as well as increase its apoptosis, while showing minimal effects against non inv(16) cell lines. As a mechanism to develop inhibitors with selectivity for the CBFβ-SMMHC fusion protein, the present invention further provides dimeric derivatives of these compounds which show both increased potency as well as selectivity for CBFβ-SMMHC. These compounds show potent inhibition of an inv(16) leukemia cell line with minimal effects on non inv(16) cell lines. Analysis of the pharmacokinetics of the developed compounds has made it possible to improve the lifetime of the compound in the plasma of mice to a level commensurate with long-term treatment.
Endothelins are powerful vasoconstrictor peptides that also play numerous other functions in many different organs. Endothelin-1 (ET-1) is the most abundant and important of this family of peptides in blood vessels. Production of ET-1 is increased in the endothelium and the kidney in salt-dependent models of hypertension ET-1 elicits an inflammatory response by increasing oxidant stress in the vascular wall, which induces vascular remodeling and endothelial dysfunction found in the hypertensive models that exhibit an endothelin-mediated component. Endothelin receptor antagonists lower blood pressure in hypertensive patients. They could become therapeutic agents for prevention of target organ damage in hypertension and in type 2 diabetes, chronic renal failure and congestive heart failure. Side effects of endothelin receptor blockers have prevented up to the present their development for these indications. Endothelin antagonists have been approved only for the treatment of pulmonary hypertension, a rapidly fatal condition in which the endothelin system plays an important role and endothelin antagonists exert favorable effects.The exact mechanism of action of ERAs on the pulmonary vascular bed remains unclear. Vasodilatation is just a part of the mechanism, since usually 70%-80% of Idiopathic PAH patients do not respond acutely to vasodilators. Endothelin is likely to be involved in pulmonary vasoconstriction, inflammation, cellular proliferation and fibrosis ie. remodelling Recent research illustrates that bosentan is capable of blunting the vascular remodelling normally associated with PAH If ERAs could prevent remodelling, they might substantially improve the long-term survival in patients with mild symptoms (WHO class II or I).

Bosentan, the most popular endothelin receptor antagonist, has been largely used in the treatment of pulmonary hypertension (PH). It can improve exercise capacity, lower Borg dyspnoea score nad these effects are usually associated with the concomitant improvement in cardiopulmonary haemodynamics.

No physiological study has so far verified the hypothesis that Bosentan may laso have an effect on the "respiratory side" of the cadio-pulmonary system (i.e. on pulmonary mechanics and work of breathing)
Excess body fat, the hallmark of obesity is a major risk factor for the development of insulin resistance (decreased insulin sensitivity), type 2 diabetes, and cardiovascular disease. Previous studies have shown that South Asians (people who originate from the Indian subcontinent) appear particularly prone to develop diabetes and heart disease compared to white Caucasians of European origin. In Canada, in the Study of Health Assessment and Risk in Ethnic groups (SHARE), it was observed that in a random selection of South Asian and European individuals, South Asians had twice as much type 2 diabetes and cardiovascular disease and were significantly more insulin resistant than Europeans despite a similar body mass index (BMI) and waist circumference. It is possible that the increased propensity of South Asians to develop insulin resistance, type 2 diabetes, and cardiovascular disease is related to greater total body fat and/or increased visceral fat in addition to the possible biological differences in adipose tissue and skeletal muscle tissues. The primary objective of this study is therefore to determine differences among age, sex, and BMI-matched people of South Asian and European Caucasian descent in body composition (specifically total body fat, lean body mass) and fat distribution (where the fat is stored in the body). This study will therefore test the hypothesis that for a similar BMI, South Asians have more total body fat and less lean body mass than age and sex-matched European Caucasians. The secondary objectives of this study are to look at the differences in the two ethnic groups at a biological level, including: differences in visceral fat, adipose tissue morphology, imflammation and adipokine production, skeletal muscle fat content, fatty acid oxidation and mitochondrial activity.
Administer RC48-ADC intravenously in combination with bevacizumab 5mg/kg once every two weeks. Medication must be discontinued until disease progression, intolerable toxicity, informed consent is withdrawn, or investigator judgment is made.
This will be an open, prospective, multi-center outcome study. This study will be conducted at up to ten centers, each of which will enroll approximately 20 patients. A maximum of 200 patients will be enrolled. This patient sample size will allow statistical comparison to historical literature and allow an inter-center comparison of outcome. Enrollment into the study may include all patients who have lumbar spinal fusion performed. All spinal fusion surgery will be performed using the EBI SpineLink® system.
FIELD: medicine.SUBSTANCE: hand burns are surgically treated and coated with gel urethane foam, LOCUS preparation. For coating, the hand is placed down without restrain on a surface covered with a sterile polyethylene film. The dorsal surface is first coated, and then the coating is applied into web spaces with fingers spread as much as possible along the full depth of the web spaces and along the finger length. The exposure is held until the coating is polymerised completely. The hand is turned up, and the palmar surface and fingers are coated with the gel urethane foam to simulate an urethane foam glove covering 2-3 cm of the intact skin and kept until the coating is polymerised completely. The hand covered with the urethane foam glove is placed into a closed container with an elastic cuff sealing the wrist; low pressure of 10-150 mm Hg is generated in the cuff within 12-48 hours. The urethane foam glove is removed as far as the wound fluid is collected with the above procedure repeated as may be required from time to time until the burn wound is epithelised, or dermoplasty appears to be indicated.EFFECT: reducing the length of treatment by creating optimum conditions for wound healing, and by providing the comfortable use of the coating.2 cl, 4 dwg, 2 ex
Ivosidenib is approved in the United States and in EU for the treatment of advanced or metastatic CCA; this study is being conducted to conslidate the data related to the safety, efficacy, and impact on quality of life for patients. This is an open-label, single-arm study of ivosidenib, which means that all patients meeting eligibility criteria will receive two 250 mg ivosidenib tablets, totaling 500mg of drug, to be taken orally, once daily, for 28 consecutive days, also referred to as one cycle. Additional cycles can continue as long as clinical benefit is confirmed by an investigator, and consent is maintained. There will be a screening visit, study visit on day 1 of each cycle, withdrawal visit within 42 days of stopping treatment, and a follow-up visit every 6 months for up to 18 months after stopping treatment. This results in a minimum of 6 study visits for the completion of one 28-day cycle of ivosidenib. One additional study visit will be added on day one of each additional cycle of treatment. Study visits will include an electrocardiogram (ECG), physical exam, tumor assessment, according to local practive at a given site and blood and urine analyses. If at any point ivosidenib is made available as a medical prescription at the patient's site, patients will be withdrawn from the study treatment and patients will be followed to collect data on overall survival.
PROBLEM TO BE SOLVED: To obtain the subject agent, having activity to couple itself with σ-receptor in a peculiar manner, and useful for the treatment of mental disorders in which σ-receptor is involved, mainly mental diseases and schizophrenia, by incorporating a specific protopine type alkaloid. SOLUTION: This agent contains a compound shown by formula I [R1 to R8 are each H, hydroxy, a 1-6C alkoxy or the like, or the one forming methylenedioxy with the adjacent one; X is O or shown by formula II; R9 is a 1-6C alkyl, 2-6C alkenyl or 3-8C cycloalkyl; and (m), (n), (o) and (p) are each 0 to 5], e.g. the one shown by formula III. The compound shown by formula I is obtained by separating, by column chromatography, dried and methanol- extracted Corydalis impatients (Pall). Fish, a medicinal plant naturally growing in China's Szechwan Province, assessing the fractions for their σ-receptor coupling inhibiting activity, repeating separation and activity assessment procedures, and finally purifying and isolating it as the single component. It may also be obtained by known synthetic procedure. It is to be administered normally at 0.1 to 500 mg a day for an adult.
Hallucinations are a core feature of psychosis, and their severity during the acute phase of illness is associated with a range of poor outcomes. Various clinical and sociodemographic factors may predict hallucinations and other positive psychotic symptoms in first episode psychosis (FEP). Despite this, the precise factors associated with hallucinations at first presentation to an early intervention service have not been extensively researched. Through detailed interviews and chart reviews, we investigated sociodemographic and clinical predictors in 636 minimally-medicated patients who entered PEPP-Montréal, an early intervention service for FEP, between 2003 and 2018. Hallucinations were measured using the Scale for the Assessment of Positive Symptoms (SAPS), while negative symptoms were assessed using the Scale for the Assessment of Negative symptoms (SANS). Depressive symptoms were evaluated through the Calgary Depression Scale for Schizophrenia (CDSS), and anxiety symptoms via the Hamilton Rating Scale for Anxiety (HAS). A majority (n = 381, 59.9 %) of the sample presented with clinically significant hallucinations (SAPS global hallucinations score ≥ 3) at program entry. These patients had an earlier age at onset, fewer years of education, and a higher severity of delusions, depression and negative symptoms than those without clinical-level hallucinations. These results suggest that individuals with clinically significant hallucinations at admission tend to be younger and have a greater overall symptom burden. This makes it especially important to monitor hallucinations alongside delusions, depression and negative symptoms in order to identify who might benefit from targeted interventions. The implications of these findings for early intervention and person-centered care are discussed.
First, participants will remain on the DBT waitlist for 12 weeks receiving no active intervention and will complete pre and post-measures. Then participants will complete 1.5 hr group sessions once per week for 12 weeks of Skills Training in Affective and Interpersonal Regulation (STAIR). Participants will complete self-report measures pre, post, and at one month intervals.
PURPOSE: To obtain the subject cosmetic safe to the human body, containing, as quality stabilizer, a combination of each specified amount of an N-coconut oil fatty acid acyl-L-arginylethyl-DL-pyrrolidonecarboxylic acid and hinokitiol. CONSTITUTION: This cosmetic contains, as quality stabilizer, a combination of 0.01-0.05wt.% of an N-coconut oil fatty acid acyl-arginylethyl-DL- pyrrolidonecarboxylic acid (salt) of the formula (RCO is a coconut oil fatty acid residue) and 0.001-0.05wt.% of hinokitiol, containing neither antioxidant nor antiseptic specified by the Pharmaceutical Affairs Law. The quality stabilizer does not induce skin chapping and inflammation, having antimicrobial capability. The compound of the formula is not only highly safe but also has a wide spectrum of high germicidal power, also being excellent in biodegradability. The hinokitiol can be extracted from evergreen trees such as hinoki, having antimicrobial capability. The above quality stabilizer is highly effective for preventing cosmetics from deterioration or putrefaction.
Methods, systems, and computer-readable media are provided for routing radio-frequency identification (RFID) location data from an RFID tag reader to a record-keeping unit. A first tagging entry is received from a first record-keeping unit. The information associated with the first tagging entry is stored in a data store. A first set of location data is received, indicating that the RFID tag of the first item has been read by an RFID tag reader. It is algorithmically determined that the received location data corresponds to the first tagging entry received from the first record-keeping unit. The first set of location data is communicated to the first record-keeping unit.
The purpose of this study is to compare the viral load, safety, tolerability, and clinical efficacy of RV521 compared to placebo. This is a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled study. Up to 200 adult subjects with a documented symptomatic RSV URTI who have undergone HCT within 1 year of randomization and who are moderately to severely immunocompromised will be randomized.

Qualified subjects will be randomized in a 1:1 ratio to receive RV521 capsules or matching placebo twice daily for 10 days. After the completion of the 10-day double-blind treatment period, subjects will be followed for an additional 28 days. Study drug may be taken on an outpatient or inpatient basis, depending on clinical status and site practices. Randomization will be stratified by type of HCT graft and ALC count. There are 9 clinic visits planned for this study.
The invention provides a traditional Chinese medicine preparation for treating constipation. The traditional Chinese medicine preparation is characterized in that a formula consists of Chinese angelica, achyranthes root, cistanche, rhizome alismatis and cimicifuga foetida and the like. The dosage forms comprise a plurality of oral preparation such as capsules, tablet, particulate agent, oral liquid, syrup and the like. The invention has the functions of kidney warming and bowel relaxing. A total effective rate of clinical treatments is 91.9% and the effective healing rate is 56.5%. The traditional Chinese medicine preparation has an obvious therapy effects on various disease symptoms such as habitual constipation, senile constipation and postpartum constipation due to kidney-yang deficiency and kidney-Jing deficiency. The traditional Chinese medicine preparation of the invention has no adverse reaction in the process of clinical observation, and is an ideal medicine for treating constipation.